{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:50:41Z","timestamp":1790383841323,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["CL-2022-07-001"],"award-info":[{"award-number":["CL-2022-07-001"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dalbavancin is a long-acting lipoglycopeptide with Gram-positive activity, licensed for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs), although off-licence use is increasingly prevalent. We describe our experience in Liverpool of using dalbavancin for off-licence indications and as a risk-reduction strategy in patients at risk of premature hospital discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients receiving dalbavancin in the period 1\/9\/2020\u201330\/4\/2024 in Liverpool were identified. Data was extracted by review of patient notes. Primary outcomes were clinical success (resolution of infection without re-admission or further antibiotics) and 90-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ninety-five individual dalbavancin courses were identified. 24\/95 were for licensed indications (i.e., ABSSSI without bacteraemia). Off-licence indications included bone and joint infections (BJIs) (30\/95), infective endocarditis (IE) (13\/95) and\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      bacteraemia (SAB) (27\/95). The clinical success rate and 90-day mortality for ABSSSI without bacteraemia were 91.67% and 4.17%, respectively. BJI without bacteraemia and SAB outcomes were similar (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.999). However, IE had worse rates of clinical success (61.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.072) and 90-day mortality (30.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042). 10\/18 PWIDs who were prematurely discharged achieved clinical success; 17\/18 were alive at 90 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The data in this retrospective analysis adds to the growing body of evidence that dalbavancin is safe and effective for the treatment of BJIs and SABs. It also reinforces the uncertainty in the literature over the efficacy of use in IE. Additionally, these data demonstrate that dalbavancin may be used successfully as a risk mitigation strategy for PWIDs who may be prematurely discharged from an inpatient stay.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-025-02585-x","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:48:44Z","timestamp":1750664924000},"page":"2503-2509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Experience of use of dalbavancin for the treatment of unlicensed indications in a UK tertiary infectious diseases setting"],"prefix":"10.1007","volume":"53","author":[{"given":"Christopher A.","family":"Darlow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Lucy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libuse","family":"Ratcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"11","key":"2585_CR1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s40265-015-0430-x","volume":"75","author":"LJ Scott","year":"2015","unstructured":"Scott LJ, Dalbavancin. A Review in Acute Bacterial Skin and Skin Structure Infections. Drugs. 2015;75(11):1281\u201391.","journal-title":"Drugs"},{"issue":"2","key":"2585_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/jac\/44.2.179","volume":"44","author":"G Candiani","year":"1999","unstructured":"Candiani G, Abbondi M, Borgonovi M, Roman\u00f2 G, Parenti F. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother. 1999;44(2):179\u201392.","journal-title":"J Antimicrob Chemother"},{"issue":"suppl2","key":"2585_CR3","doi-asserted-by":"publisher","first-page":"ii15","DOI":"10.1093\/jac\/dki005","volume":"55","author":"A Malabarba","year":"2005","unstructured":"Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005;55(suppl2):ii15\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2585_CR4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","volume":"48","author":"A Leighton","year":"2004","unstructured":"Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, et al. Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy Volunteers. Antimicrob Agents Chemother. 2004;48(3):940\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2585_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpdd.695","volume":"9","author":"TJ Carrothers","year":"2020","unstructured":"Carrothers TJ, Chittenden JT, Critchley I. Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis. Clin Pharmacol Drug Dev. 2020;9(1):21\u201331.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"23","key":"2585_CR6","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection. N Engl J Med. 2014;370(23):2169\u201379.","journal-title":"N Engl J Med"},{"issue":"3","key":"2585_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40121-024-00933-2","volume":"13","author":"N Rebold","year":"2024","unstructured":"Rebold N, Alosaimy S, Pearson JC, Dionne B, Taqi A, Lagnf A, et al. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study. Infect Dis Ther. 2024;13(3):565\u201379.","journal-title":"Infect Dis Ther"},{"issue":"10","key":"2585_CR8","first-page":"700","volume":"9","author":"L Ajaka","year":"2020","unstructured":"Ajaka L, Heil E, Schmalzle S. Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care. Antibiot Basel Switz. 2020;9(10):700.","journal-title":"Antibiot Basel Switz"},{"issue":"2","key":"2585_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.eimc.2024.02.010","volume":"43","author":"A Salinas-Botr\u00e1n","year":"2025","unstructured":"Salinas-Botr\u00e1n A, Olmos-Blanco C, Fern\u00e1ndez de Velasco-P\u00e9rez D, Guzm\u00e1n-Carreras A, Morales-Rosas A, G\u00f3mez-Ram\u00edrez D. Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years. Enfermedades Infecc Microbiol Clin Engl Ed. 2025;43(2):71\u20139.","journal-title":"Enfermedades Infecc Microbiol Clin Engl Ed"},{"issue":"1","key":"2585_CR10","doi-asserted-by":"publisher","first-page":"106842","DOI":"10.1016\/j.ijantimicag.2023.106842","volume":"62","author":"JD Frazier","year":"2023","unstructured":"Frazier JD, Stoudenmire LL, Wagner JL, Thomas GM, Steele GM, Henao-Mart\u00ednez AF, et al. Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2023;62(1):106842.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"2585_CR11","doi-asserted-by":"publisher","first-page":"ofac335","DOI":"10.1093\/ofid\/ofac335","volume":"9","author":"KC Molina","year":"2022","unstructured":"Molina KC, Lunowa C, Lebin M, Segerstrom Nunez A, Azimi SF, Krsak M, et al. Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections. Open Forum Infect Dis. 2022;9(7):ofac335.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2585_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40121-021-00568-7","volume":"11","author":"PL Gonzalez","year":"2022","unstructured":"Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, Puttagunta S, Dunne MW. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials. Infect Dis Ther. 2022;11(1):423\u201334.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"2585_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s15010-024-02393-9","volume":"53","author":"GM Leanza","year":"2025","unstructured":"Leanza GM, Rando E, Frondizi F, Taddei E, Giovannenze F, Horcajada JP, et al. A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis. Infection. 2025;53(1):15\u201323.","journal-title":"Infection"},{"issue":"2","key":"2585_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.eimc.2024.04.009","volume":"43","author":"E Aparicio-Minguij\u00f3n","year":"2025","unstructured":"Aparicio-Minguij\u00f3n E, Bo\u00e1n J, Terr\u00f3n A, Heredia C, Puente C, P\u00e9rez-Jacoiste As\u00edn A, et al. Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients. Enfermedades Infecc Microbiol Clin Engl Ed. 2025;43(2):86\u201392.","journal-title":"Enfermedades Infecc Microbiol Clin Engl Ed"},{"key":"2585_CR15","first-page":"41","volume":"138","author":"M Su\u00e1rez","year":"2024","unstructured":"Su\u00e1rez M, P\u00e9rez-Landeiro A, Sanjurjo A, Lima O, Sousa A, L\u00f3pez A, et al. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2024;138:41\u20135.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"issue":"3","key":"2585_CR16","doi-asserted-by":"publisher","first-page":"106918","DOI":"10.1016\/j.ijantimicag.2023.106918","volume":"62","author":"C Hidalgo-Tenorio","year":"2023","unstructured":"Hidalgo-Tenorio C, Sadyrbaeva-Dolgova S, Enr\u00edquez-G\u00f3mez A, Mu\u00f1oz P, Plata-Ciezar A, Mir\u00f3 JM, et al. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential\/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci. Int J Antimicrob Agents. 2023;62(3):106918.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"2585_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1080\/1120009X.2020.1823119","volume":"33","author":"E Durante-Mangoni","year":"2021","unstructured":"Durante-Mangoni E, Boccia F, Ursi MP, Karruli A, Andini R, Galdo M, et al. Dalbavancin for infective endocarditis: a single centre experience. J Chemother Florence Italy. 2021;33(4):256\u201362.","journal-title":"J Chemother Florence Italy"},{"issue":"5","key":"2585_CR18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;67(5):795\u20138.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"7","key":"2585_CR19","first-page":"1005","volume":"16","author":"S Lovatti","year":"2023","unstructured":"Lovatti S, Tiecco G, Mul\u00e9 A, Rossi L, Sforza A, Salvi M, et al. Dalbavancin in Bone and Joint Infections: A Systematic Review. Pharm Basel Switz. 2023;16(7):1005.","journal-title":"Pharm Basel Switz"},{"issue":"10","key":"2585_CR20","first-page":"1492","volume":"12","author":"D Dimopoulou","year":"2023","unstructured":"Dimopoulou D, Mantadakis E, Koutserimpas C, Samonis G. A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections. Antibiot Basel Switz. 2023;12(10):1492.","journal-title":"Antibiot Basel Switz"},{"issue":"2","key":"2585_CR21","doi-asserted-by":"publisher","first-page":"ofab589","DOI":"10.1093\/ofid\/ofab589","volume":"9","author":"AR Cain","year":"2022","unstructured":"Cain AR, Bremmer DN, Carr DR, Buchanan C, Jacobs M, Walsh TL, et al. Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis. Open Forum Infect Dis. 2022;9(2):ofab589.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2585_CR22","doi-asserted-by":"publisher","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","volume":"6","author":"U Rappo","year":"2019","unstructured":"Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, et al. Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety. Open Forum Infect Dis. 2019;6(1):ofy331.","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"2585_CR23","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1093\/jac\/dkad331","volume":"78","author":"C Hervochon","year":"2023","unstructured":"Hervochon C, Hennart B, Leroy AG, Corvec S, Boutoille D, Senneville \u00c9, et al. Dalbavancin plasma concentrations in 133 patients: a PK\/PD observational study. J Antimicrob Chemother. 2023;78(12):2919\u201325.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"2585_CR24","doi-asserted-by":"publisher","first-page":"e049733","DOI":"10.1136\/bmjopen-2021-049733","volume":"11","author":"M Dimitrova","year":"2021","unstructured":"Dimitrova M, Gilchrist M, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses. BMJ Open. 2021;11(9):e049733.","journal-title":"BMJ Open"},{"issue":"1","key":"2585_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s13063-022-06370-1","volume":"23","author":"NA Turner","year":"2022","unstructured":"Turner NA, Zaharoff S, King H, Evans S, Hamasaki T, Lodise T, et al. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Trials. 2022;23(1):407.","journal-title":"Trials"},{"issue":"5","key":"2585_CR26","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/cid\/ciad119","volume":"77","author":"S Freling","year":"2023","unstructured":"Freling S, Wald-Dickler N, Banerjee J, Canamar CP, Tangpraphaphorn S, Bruce D, et al. Real-World Application of Oral Therapy for Infective Endocarditis: A Multicenter, Retrospective, Cohort Study. Clin Infect Dis. 2023;77(5):672\u20139.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2585_CR27","first-page":"1063","volume":"13","author":"G Parruti","year":"2024","unstructured":"Parruti G, Polilli E, Coladonato S, Rapacchiale G, Trave F, Mazzotta E, et al. Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin\/Soft Tissue and Other Difficult-to-Treat Infections. Antibiot Basel Switz. 2024;13(11):1063.","journal-title":"Antibiot Basel Switz"},{"issue":"4","key":"2585_CR28","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s15010-024-02176-2","volume":"52","author":"S Esposito","year":"2024","unstructured":"Esposito S, Pagliano P, De Simone G, Guarino A, Pan A, Brambilla P, et al. In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry. Infection. 2024;52(4):1297\u2013306.","journal-title":"Infection"},{"issue":"4","key":"2585_CR29","doi-asserted-by":"publisher","first-page":"ofae186","DOI":"10.1093\/ofid\/ofae186","volume":"11","author":"S Zambrano","year":"2024","unstructured":"Zambrano S, Paras ML, Suzuki J, Pearson JC, Dionne B, Schrager H, et al. Real-World Dalbavancin Use for Serious Gram-Positive Infections: Comparing Outcomes Between People Who Use and Do Not Use Drugs. Open Forum Infect Dis. 2024;11(4):ofae186.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2585_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s15010-023-02152-2","volume":"52","author":"JC McSorley","year":"2024","unstructured":"McSorley JC, Reyes D, Tonna I, Bateman V. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service. Infection. 2024;52(2):567\u201376.","journal-title":"Infection"},{"issue":"1","key":"2585_CR31","doi-asserted-by":"publisher","first-page":"e0238522","DOI":"10.1128\/spectrum.02385-22","volume":"11","author":"R Lueking","year":"2023","unstructured":"Lueking R, Wei W, Mang NS, Ortwine JK, Meisner J. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital. Microbiol Spectr. 2023;11(1):e0238522.","journal-title":"Microbiol Spectr"},{"issue":"8","key":"2585_CR32","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1093\/jac\/dkz162","volume":"74","author":"T Morrisette","year":"2019","unstructured":"Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. J Antimicrob Chemother. 2019;74(8):2405\u201316.","journal-title":"J Antimicrob Chemother"},{"key":"2585_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jgar.2024.06.002","volume":"38","author":"G Zhanel","year":"2024","unstructured":"Zhanel G, Silverman M, Malhotra J, Baxter M, Rahimi R, Irfan N, et al. Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. J Glob Antimicrob Resist. 2024;38:154\u20137.","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"2585_CR34","doi-asserted-by":"publisher","first-page":"dlae066","DOI":"10.1093\/jacamr\/dlae066","volume":"6","author":"C Bresges","year":"2024","unstructured":"Bresges C, Bresges K, Hewitt C, Sharma S, Davies B. Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs. JAC-Antimicrob Resist. 2024;6(3):dlae066.","journal-title":"JAC-Antimicrob Resist"},{"issue":"2","key":"2585_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","volume":"8","author":"JT Bork","year":"2019","unstructured":"Bork JT, Heil EL, Berry S, Lopes E, Dav\u00e9 R, Gilliam BL, et al. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections. Infect Dis Ther. 2019;8(2):171\u201384.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"2585_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","volume":"51","author":"E Bouza","year":"2018","unstructured":"Bouza E, Valerio M, Soriano A, Morata L, Carus EG, Rodr\u00edguez-Gonz\u00e1lez C, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51(4):571\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2585_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.mcna.2021.08.006","volume":"106","author":"LR Marks","year":"2022","unstructured":"Marks LR, Nolan NS, Liang SY, Durkin MJ, Weimer MB. Infectious Complications of Injection Drug Use. Med Clin North Am. 2022;106(1):187\u2013200.","journal-title":"Med Clin North Am"},{"issue":"4","key":"2585_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/08897077.2019.1671942","volume":"41","author":"R Simon","year":"2020","unstructured":"Simon R, Snow R, Wakeman S. Understanding why patients with substance use disorders leave the hospital against medical advice: A qualitative study. Subst Abuse. 2020;41(4):519\u201325.","journal-title":"Subst Abuse"},{"issue":"12","key":"2585_CR39","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.2105\/AJPH.2015.302885","volume":"105","author":"L Ti","year":"2015","unstructured":"Ti L, Ti L. Leaving the Hospital Against Medical Advice Among People Who Use Illicit Drugs: A Systematic Review. Am J Public Health. 2015;105(12):e53\u20139.","journal-title":"Am J Public Health"},{"issue":"3","key":"2585_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10096-018-03461-3","volume":"38","author":"K O\u2019Callaghan","year":"2019","unstructured":"O\u2019Callaghan K, Tapp S, Hajkowicz K, Legg A, McCarthy KL. Outcomes of patients with a history of injecting drug use and receipt of outpatient antimicrobial therapy. Eur J Clin Microbiol Infect Dis. 2019;38(3):575\u201380.","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02585-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T08:52:29Z","timestamp":1764751949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02585-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2585"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02585-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}